ENSC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 107400 min ago

@ $0.897

Išleistas: 14 vas. 2024 @ 22:28

Grąža: -34.84%

Ankstesnis signalas: vas. 14 - 17:42

Ankstesnis signalas: Pardavimas

Grąža: -0.39 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	176 491
Vidutinė apimtis	540 200
Rinkos kapitalizacija	4.28M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0100 (1.71%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-02	Gower Bob G	Buy	90 287	Common Stock
2023-03-01	Gower Bob G	Buy	270 000	Common Stock
2023-02-28	Gower Bob G	Buy	109 300	Common Stock
2022-12-09	Gower Bob G	Buy	357 143	Common Stock
2022-12-09	Gower Bob G	Buy	714 286	Warrants

INSIDER POWER
99.26
Last 80 transactions
Buy: 23 095 136 \| Sell: 3 675 006

Tūris Koreliacija

Ilgas: 0.13 (neutral)

Trumpas: 0.26 (neutral)

Signal:(46.493) Neutral

Ensysce Biosciences, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVAC	0.928
PAIC	0.905
PRVB	0.904
SVOK	0.878
ALR	0.862
TLGT	0.852
ALLR	0.847
LKCO	0.844
RDHL	0.843
ELEV	0.839

10 Labiausiai neigiamai susiję koreliacijos
NETE	-0.92
LWAC	-0.92
MDRRP	-0.916
SRAC	-0.904
WSBCP	-0.895
RAVN	-0.889
HNST	-0.889
OVBC	-0.886
MRBK	-0.885
MNSBP	-0.883

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Ensysce Biosciences, Inc. Koreliacija - Valiuta/Žaliavos

0.36
( neutral )

0.62
( weak )

0.00
( neutral )

-0.15
( neutral )

0.33
( neutral )

Ensysce Biosciences, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$2.23M
Bruto pelnas:	$-5.36M (-240.17 %)
EPS:	$-4.69

FY	2023
Pajamos:	$2.23M
Bruto pelnas:	$-5.36M (-240.17 %)
EPS:	$-4.69

FY	2022
Pajamos:	$2.52M
Bruto pelnas:	$-17.31M (-686.08 %)
EPS:	$-138.73

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-29.60

Financial Reports:

No articles found.

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.